You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTestosterone
Accession NumberDB00624  (APRD00433, DB05275)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionTestosterone is a steroid sex hormone found in both men and women. In men, testosterone is produced primarily by the Leydig (interstitial) cells of the testes when stimulated by luteinizing hormone (LH). It functions to stimulate spermatogenesis, promote physical and functional maturation of spermatozoa, maintain accessory organs of the male reproductive tract, support development of secondary sexual characteristics, stimulate growth and metabolism throughout the body and influence brain development by stimulating sexual behaviors and sexual drive. In women, testosterone is produced by the ovaries (25%), adrenals (25%) and via peripheral conversion from androstenedione (50%). Testerone in women functions to maintain libido and general wellbeing. Testosterone exerts a negative feedback mechanism on pituitary release of LH and follicle-stimulating hormone (FSH). Testosterone may be further converted to dihydrotestosterone or estradiol depending on the tissue.
Structure
Thumb
Synonyms
17beta-hydroxy-4-androsten-3-one
17beta-Hydroxy-4-androsten-3-one
4-Androsten-17beta-ol-3-one
4-androsten-17β-ol-3-one
Androderm
Depo-Testadiol
Mertestate
Synandrol F
Testosteron
Testosterona
Testostérone
Testosteronum
Testoxyl
Testryl
Virosterone
External Identifiers
  • 4-08-00-00979
  • BRN 3170544
  • CCRIS 7082
  • EINECS 206-253-5
  • EINECS 227-712-6
  • NSC-17591
  • Org 538
  • UNII-7Z6522T8N9
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AndriolCapsule40 mgOralMerck Canada Inc1992-12-31Not applicableCanada
AndrodermPatch2 mg/dTransdermalAllergan, Inc.1995-09-29Not applicableUs
AndrodermPatch24.3 mgTransdermalActavis Specialty Pharmaceuticals Co2002-09-24Not applicableCanada
AndrodermPatch4 mg/dTransdermalAllergan, Inc.1995-09-29Not applicableUs
AndrodermPatch2 mg/dTransdermalActavis Pharma, Inc.1995-09-29Not applicableUs
AndrodermPatch12.2 mgTransdermalActavis Specialty Pharmaceuticals Co2000-12-19Not applicableCanada
AndrodermPatch4 mg/dTransdermalActavis Pharma, Inc.1995-09-29Not applicableUs
AndrogelGel1 %TopicalBgp Pharma Ulc2004-09-20Not applicableCanada
AndrogelGel10 mg/gTransdermalAbb Vie Inc.2011-03-142016-02-18Us
AndrogelGel10 mg/gTransdermalPhysicians Total Care, Inc.2003-06-05Not applicableUs
AndrogelGel10 mg/gTransdermalA S Medication Solutions Llc2011-03-14Not applicableUs
AndrogelGel10 mg/gTransdermalAbb Vie Inc.2011-03-14Not applicableUs
AndrogelGel16.2 mg/gTransdermalA S Medication Solutions Llc2011-04-29Not applicableUs
AndrogelGel1 %TopicalBgp Pharma Ulc2002-05-06Not applicableCanada
AndrogelGel10 mg/gTransdermalRebel Distributors Corp.2003-06-05Not applicableUs
AndrogelGel16.2 mg/gTransdermalAbb Vie Inc.2011-04-29Not applicableUs
AndrogelGel10 mg/gTransdermalPhysicians Total Care, Inc.2007-08-29Not applicableUs
AndrogelGel16.2 mg/gTransdermalA S Medication Solutions Llc2011-04-29Not applicableUs
AndrogelGel1 %TopicalBgp Pharma Ulc2002-05-06Not applicableCanada
AndrogelGel10 mg/gTransdermalAbb Vie Inc.2011-03-14Not applicableUs
AndrogelGel10 mg/gTransdermalPhysicians Total Care, Inc.2003-05-15Not applicableUs
AveedInjection250 mg/mLIntramuscularEndo Pharmaceuticals Solutions Inc.2014-03-05Not applicableUs
AxironSolution30 mg/1.5mLTopicalEli Lilly and Company2010-11-23Not applicableUs
AxironSolution30 mg/1.5mLTopicalPhysicians Total Care, Inc.2013-09-06Not applicableUs
AxironSolution2 %TopicalEli Lilly Canada Inc2013-05-08Not applicableCanada
DelatestrylSolution200 mgIntramuscularValeant Canada Lp Valeant Canada S.E.C.1955-12-31Not applicableCanada
DelatestrylInjection, solution200 mg/mLIntramuscularEndo Pharmaceuticals Solutions Inc.1953-12-242016-10-13Us
Depo-testosterone Inj 100mg/mlSolution100 mgIntramuscularPfizer Canada Inc1953-12-31Not applicableCanada
FortestaGel, metered10 mg/.5gTopicalEndo Pharmaceuticals Inc.2010-12-29Not applicableUs
Malogen Aqueous 100 Sus 100mg/mlSuspension100 mgIntramuscularGermiphene Corporation1994-12-311998-08-13Canada
Malogex La200 Liq 200mg/mlLiquid200 mgIntramuscularGermiphene Corporation1995-12-311998-08-13Canada
NatestoGel5.5 mg/1NasalEndo Pharmaceuticals2015-03-122018-05-31Us
NatestoGel4.5 %NasalAcerus Pharmaceuticals Srl2016-05-06Not applicableCanada
PMS-testosteroneCapsule40 mgOralPharmascience Inc2009-10-08Not applicableCanada
PMS-testosterone Enanthate Inj 200mg/ml USPLiquid200 mgIntramuscularPharmascience Inc1991-12-31Not applicableCanada
Scheinpharm Testone-cyp Inject.- Im 100mg/mlLiquid100 mgIntramuscularSchein Pharmaceutical Canada Inc.1996-12-122004-07-26Canada
StriantTablet30 mg/1BuccalColumbia Laboratories, Inc.2003-06-19Not applicableUs
StriantTablet30 mg/1BuccalEndo Pharmaceuticals, Inc.2003-06-19Not applicableUs
Taro-testosteroneCapsule40 mgOralTaro Pharmaceuticals Inc2014-09-02Not applicableCanada
TestimGel50 mg/5gTransdermalA S Medication Solutions Llc2002-10-31Not applicableUs
TestimGel50 mg/5gTransdermalEndo Pharmaceuticals, Inc.2002-10-31Not applicableUs
TestimGel50 mg/5gTopicalStat Rx USA2002-10-31Not applicableUs
TestimGel50 mg/5gTransdermalPhysicians Total Care, Inc.2004-01-29Not applicableUs
TestimGel50 mg/5gTransdermalA S Medication Solutions Llc2002-10-31Not applicableUs
TestimGel50 mg/5gTransdermalLake Erie Medical DBA Quality Care Products LLC2002-10-31Not applicableUs
Testim 1%Gel1 %TopicalAuxilium Pharmaceuticals Inc2007-04-17Not applicableCanada
TestosteroneGel, metered10 mg/.5gTopicalQualitest Pharmaceuticals2014-08-25Not applicableUs
TestosteroneGel50 mg/5gTransdermalPrasco Laboratories2014-06-09Not applicableUs
TestosteroneGel50 mg/5gTopicalUpsher Smith Laboratories, Inc.2014-06-16Not applicableUs
TestosteroneGel12.5 mg/1.25gTopicalPerrigo New York Inc2014-12-27Not applicableUs
TestosteroneGel, metered12.5 mg/1TopicalUpsher Smith Laboratories, Inc.2014-06-16Not applicableUs
Testosterone Cypionate Injection USPLiquid100 mgIntramuscularSandoz Canada Incorporated2002-08-01Not applicableCanada
Testosterone Cypionate Injection, USPLiquid100 mgIntramuscularSterimax Inc1992-12-31Not applicableCanada
Testosterone Enanthate Inj 200mg/mlLiquid200 mgIntramuscularTaro Pharmaceuticals Inc1988-12-312001-08-21Canada
VogelxoGel50 mg/5gTopicalUpsher Smith Laboratories, Inc.2014-06-09Not applicableUs
VogelxoGel, metered12.5 mg/1TopicalUpsher Smith Laboratories, Inc.2014-06-09Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AndrogelGel25 mg/2.5gTransdermalPar Pharmaceutical Inc.2015-08-10Not applicableUs
AndrogelGel50 mg/5gTransdermalPar Pharmaceutical Inc.2015-08-10Not applicableUs
Depo-testosteroneInjection, solution100 mg/mLIntramuscularPharmacia and Upjohn Company1979-07-25Not applicableUs
Depo-testosteroneInjection, solution100 mg/mLIntramuscularPharmacia And Upjohn Company Llc2014-07-01Not applicableUs
Depo-testosteroneInjection, solution200 mg/mLIntramuscularPharmacia and Upjohn Company1979-07-25Not applicableUs
Depo-testosteroneInjection, solution100 mg/mLIntramuscularA S Medication Solutions Llc1979-07-25Not applicableUs
Depo-testosteroneInjection, solution200 mg/mLIntramuscularPharmacia And Upjohn Company Llc2014-07-01Not applicableUs
Depo-testosteroneInjection, solution200 mg/mLIntramuscularPhysicians Total Care, Inc.1994-07-12Not applicableUs
Depo-testosteroneInjection, solution100 mg/mLIntramuscularA S Medication Solutions Llc1979-07-25Not applicableUs
Depo-testosteroneInjection, solution200 mg/mLIntramuscularPharmacia And Upjohn Company Llc2014-03-31Not applicableUs
Depo-testosteroneInjection, solution200 mg/mLIntramuscularA S Medication Solutions Llc1979-07-25Not applicableUs
TestopelPellet75 mg/1SubcutaneousSlate Pharma2009-07-21Not applicableUs
TestopelPellet75 mg/1SubcutaneousEndo Pharmaceuticals, Inc.2014-10-31Not applicableUs
TestosteroneGel10 mg/gTransdermalActavis Pharma, Inc.2015-11-092016-01-07Us
TestosteroneGel10 mg/gTransdermalActavis Pharma, Inc.2015-11-09Not applicableUs
TestosteroneGel10 mg/gTransdermalActavis Pharma, Inc.2015-11-09Not applicableUs
TestosteroneGel10 mg/gTransdermalActavis Pharma, Inc.2015-11-09Not applicableUs
Testosterone CypionateInjection200 mg/mLIntramuscularProficient Rx LP2012-05-01Not applicableUs
Testosterone CypionateInjection, solution200 mg/mLIntramuscularA S Medication Solutions Llc2011-05-04Not applicableUs
Testosterone CypionateInjection, solution100 mg/mLIntramuscularHospira, Inc.2016-08-01Not applicableUs
Testosterone CypionateInjection200 mg/mLIntramuscularA S Medication Solutions Llc2012-05-01Not applicableUs
Testosterone CypionateInjection200 mg/mLIntramuscularWest Ward Pharmaceuticals Corp2012-05-01Not applicableUs
Testosterone CypionateInjection, solution100 mg/mLIntramuscularPhysicians Total Care, Inc.2006-08-10Not applicableUs
Testosterone CypionateInjection, solution200 mg/mLIntramuscularSun Pharmaceutical Industries Limited2013-06-17Not applicableUs
Testosterone CypionateInjection, solution200 mg/mLIntramuscularHospira, Inc.2016-08-01Not applicableUs
Testosterone CypionateInjection, solution200 mg/mLIntramuscularPaddock Laboratories, LLC2007-12-21Not applicableUs
Testosterone CypionateInjection, solution200 mg/mLIntramuscularA S Medication Solutions Llc2011-05-04Not applicableUs
Testosterone CypionateInjection, solution200 mg/mLIntramuscularDispensing Solutions, Inc.2011-05-04Not applicableUs
Testosterone CypionateInjection, solution100 mg/mLIntramuscularSun Pharmaceutical Industries Limited2013-06-17Not applicableUs
Testosterone CypionateInjection, solution200 mg/mLIntramuscularPaddock Laboratories, LLC2014-05-01Not applicableUs
Testosterone CypionateInjection, solution200 mg/mLIntramuscularActavis Pharma, Inc.2011-05-042017-05-31Us
Testosterone CypionateInjection200 mg/mLIntramuscularActavis Pharma, Inc.2015-03-05Not applicableUs
Testosterone CypionateInjection, solution200 mg/mLIntramuscularPhysicians Total Care, Inc.2007-08-10Not applicableUs
Testosterone CypionateInjection, solution200 mg/mLIntramuscularSun Pharmaceutical Industries Limited2013-06-17Not applicableUs
Testosterone CypionateInjection200 mg/mLIntramuscularWest Ward Pharmaceuticals Corp2012-05-01Not applicableUs
Testosterone EnanthateInjection, solution200 mg/mLIntramuscularWatson Laboratories, Inc.2011-05-04Not applicableUs
Testosterone EnanthateInjection, solution200 mg/mLIntramuscularWest Ward Pharmaceuticals Corp2012-09-18Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
IntrinsaPatch300 micrograms/24hoursTransdermalWarner Chilcott Uk Ltd.2006-07-28Not applicableEu
IntrinsaPatch300 micrograms/24hoursTransdermalWarner Chilcott Uk Ltd.2006-07-28Not applicableEu
IntrinsaPatch300 micrograms/24hoursTransdermalWarner Chilcott Uk Ltd.2006-07-28Not applicableEu
LivensaPatch300 micrograms/24hoursTransdermalWarner Chilcott  Deutschland Gmb H2006-07-28Not applicableEu
LivensaPatch300 micrograms/24hoursTransdermalWarner Chilcott  Deutschland Gmb H2006-07-28Not applicableEu
LivensaPatch300 micrograms/24hoursTransdermalWarner Chilcott  Deutschland Gmb H2006-07-28Not applicableEu
TestosteronePellet100 mg/1OralQualgen Llc2015-09-01Not applicableUs
TestosteronePellet50 mg/1OralQualgen Llc2015-09-01Not applicableUs
TestosteronePellet200 mg/1OralQualgen Llc2015-09-01Not applicableUs
TestosteronePellet87.5 mg/1OralQualgen Llc2015-09-01Not applicableUs
TestosteronePellet25 mg/1OralQualgen Llc2015-09-01Not applicableUs
TestosteronePellet37.5 mg/1OralQualgen Llc2015-09-01Not applicableUs
International Brands
NameCompany
Andronate 100Not Available
Andronate 200Not Available
AndropatchGlaxoSmithKline
Andropository 200Not Available
Andryl 200Not Available
Bio-T-GelBioSante Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc.
FortigelNot Available
IntrinsaProcter & Gamble
LivensaProcter & Gamble
NebidoBayer
SustanonOrganon
Testamone 100Not Available
Testaqua IMNot Available
TestodermNot Available
Testoderm TTSNot Available
TestogelBayer
TestolinNot Available
TestopatchPierre Fabre
Testopel PelletsNot Available
Testrin-P.ANot Available
Testro AQNot Available
TostrelleNot Available
TostrexNot Available
VirormoneNordic Pharma
Brand mixtures
NameLabellerIngredients
Neo Pause InjectionNeolab Inc
Salts
Name/CASStructureProperties
Testosterone Cypionate
ThumbNot applicableDBSALT001298
Testosterone Enanthate
ThumbNot applicableDBSALT001030
Testosterone Heptanoate
ThumbNot applicableDBSALT001031
Testosterone Propionate
ThumbNot applicableDBSALT001032
Testosterone Undecanoate
ThumbNot applicableDBSALT001033
Categories
UNII3XMK78S47O
CAS number58-22-0
WeightAverage: 288.4244
Monoisotopic: 288.20893014
Chemical FormulaC19H28O2
InChI KeyMUMGGOZAMZWBJJ-DYKIIFRCSA-N
InChI
InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1
IUPAC Name
(1S,2R,10R,11S,14S,15S)-14-hydroxy-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-5-one
SMILES
[H][C@@]12CC[[email protected]](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
Pharmacology
IndicationTo be used as hormone replacement or substitution of diminished or absent endogenous testosterone. Use in males: For management of congenital or acquired hypogonadism, hypogonadism associated with HIV infection, and male climacteric (andopause). Use in females: For palliative treatment of androgen-responsive, advanced, inoperable, metastatis (skeletal) carcinoma of the breast in women who are 1-5 years postmenopausal; testosterone esters may be used in combination with estrogens in the management of moderate to severe vasomotor symptoms associated with menopause in women who do not respond to adequately to estrogen therapy alone.
Structured Indications
PharmacodynamicsTestosterone is a steroid hormone from the androgen group. Testosterone is primarily secreted from the testes of males. In females, it is produced in the ovaries, adrenal glands and by conversion of adrostenedione in the periphery. It is the principal male sex hormone and an anabolic steroid. In both males and females, it plays key roles in health and well-being. Examples include enhanced libido, energy, immune function, and protection against osteoporosis. On average, the adult male body produces about twenty times the amount of testosterone than an adult female's body does.
Mechanism of actionThe effects of testosterone in humans and other vertebrates occur by way of two main mechanisms: by activation of the androgen receptor (directly or as DHT), and by conversion to estradiol and activation of certain estrogen receptors. Free testosterone (T) is transported into the cytoplasm of target tissue cells, where it can bind to the androgen receptor, or can be reduced to 5α-dihydrotestosterone (DHT) by the cytoplasmic enzyme 5α-reductase. DHT binds to the same androgen receptor even more strongly than T, so that its androgenic potency is about 2.5 times that of T. The T-receptor or DHT-receptor complex undergoes a structural change that allows it to move into the cell nucleus and bind directly to specific nucleotide sequences of the chromosomal DNA. The areas of binding are called hormone response elements (HREs), and influence transcriptional activity of certain genes, producing the androgen effects.
TargetKindPharmacological actionActionsOrganismUniProt ID
Androgen receptorProteinyes
agonist
HumanP10275 details
Related Articles
AbsorptionApproximately 10% of the testosterone dose applied on the skin surface is absorbed into systemic circulation
Volume of distributionNot Available
Protein binding40% of testosterone in plasma is bound to sex hormone-binding globulin and 2% remains unbound and the rest is bound to albumin and other proteins.
Metabolism

Testosterone is metabolized to 17-keto steroids through two different pathways. The major active metabolites are estradiol and dihydrotestosterone (DHT).

SubstrateEnzymesProduct
Testosterone
6-beta-hydroxytestosteroneDetails
Testosterone
EstradiolDetails
Testosterone
Not Available
Testosterone sulfateDetails
Testosterone
DihydrotestosteroneDetails
Testosterone
Not Available
Testosterone glucuronideDetails
Testosterone
Not Available
5-alpha-Dihydrotestosterone glucuronideDetails
Testosterone
Not Available
5a-Dihydrotestosterone sulfateDetails
Testosterone
Not Available
17-Hydroxyandrostane-3-glucuronideDetails
Route of eliminationAbout 90% of a dose of testosterone given intramuscularly is excreted in the urine as glucuronic and sulfuric acid conjugates of testosterone and its metabolites; about 6% of a dose is excreted in the feces, mostly in the unconjugated form.
Half life10-100 minutes
ClearanceNot Available
ToxicitySide effects include amnesia, anxiety, discolored hair, dizziness, dry skin, hirsutism, hostility, impaired urination, paresthesia, penis disorder, peripheral edema, sweating, and vasodilation.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Aromatase deficiencyDiseaseSMP00565
17-Beta Hydroxysteroid Dehydrogenase III DeficiencyDiseaseSMP00356
Androgen and Estrogen MetabolismMetabolicSMP00068
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the fluid retaining activities of Testosterone.Investigational
19-norandrostenedione19-norandrostenedione may increase the fluid retaining activities of Testosterone.Experimental, Illicit
4-Androstenedione4-Androstenedione may increase the fluid retaining activities of Testosterone.Experimental, Illicit
5-androstenedione5-androstenedione may increase the fluid retaining activities of Testosterone.Experimental, Illicit
AbirateroneThe serum concentration of Testosterone can be increased when it is combined with Abiraterone.Approved
AcarboseTestosterone may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Testosterone.Approved
AcenocoumarolTestosterone may increase the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Testosterone.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Testosterone.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Testosterone.Approved
AlbiglutideTestosterone may increase the hypoglycemic activities of Albiglutide.Approved
AlclometasoneAlclometasone may increase the fluid retaining activities of Testosterone.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Testosterone.Experimental
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Testosterone.Approved, Investigational
AlogliptinTestosterone may increase the hypoglycemic activities of Alogliptin.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Testosterone.Approved, Investigational
AmcinonideAmcinonide may increase the fluid retaining activities of Testosterone.Approved
AmiodaroneThe metabolism of Testosterone can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Testosterone.Approved
AnecortaveAnecortave may increase the fluid retaining activities of Testosterone.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Testosterone.Approved
AprepitantThe serum concentration of Testosterone can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Testosterone.Approved, Investigational
ArmodafinilThe metabolism of Testosterone can be decreased when combined with Armodafinil.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Testosterone.Approved, Investigational
AtazanavirThe metabolism of Testosterone can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Testosterone.Approved
AtomoxetineThe metabolism of Testosterone can be decreased when combined with Atomoxetine.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Testosterone.Approved, Investigational
BeclomethasoneBeclomethasone may increase the fluid retaining activities of Testosterone.Investigational
Beclomethasone dipropionateBeclomethasone dipropionate may increase the fluid retaining activities of Testosterone.Approved, Investigational
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Testosterone.Approved, Vet Approved
BetamethasoneBetamethasone may increase the fluid retaining activities of Testosterone.Approved, Vet Approved
BexaroteneThe serum concentration of Testosterone can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe metabolism of Testosterone can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Testosterone can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Testosterone can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Testosterone.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Testosterone.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Testosterone.Approved, Investigational
BudesonideBudesonide may increase the fluid retaining activities of Testosterone.Approved
C1 Esterase Inhibitor (Human)Testosterone may increase the thrombogenic activities of C1 Esterase Inhibitor (Human).Approved
C1 Esterase Inhibitor (Recombinant)Testosterone may increase the thrombogenic activities of C1 Esterase Inhibitor (Recombinant).Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Testosterone.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Testosterone.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Testosterone.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Testosterone.Approved
CapecitabineThe metabolism of Testosterone can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineThe metabolism of Testosterone can be increased when combined with Carbamazepine.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Testosterone.Approved
CelecoxibThe metabolism of Testosterone can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Testosterone can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Testosterone.Withdrawn
ChloramphenicolThe metabolism of Testosterone can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Testosterone.Approved, Vet Approved
ChlorpropamideTestosterone may increase the hypoglycemic activities of Chlorpropamide.Approved
CholecalciferolThe metabolism of Testosterone can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CiclesonideCiclesonide may increase the fluid retaining activities of Testosterone.Approved, Investigational
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Testosterone.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Testosterone.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Testosterone.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Testosterone.Approved
ClarithromycinThe metabolism of Testosterone can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Testosterone can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Testosterone.Approved, Illicit
ClobetasolClobetasol may increase the fluid retaining activities of Testosterone.Investigational
Clobetasol propionateClobetasol propionate may increase the fluid retaining activities of Testosterone.Approved
ClocortoloneClocortolone may increase the fluid retaining activities of Testosterone.Approved
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Testosterone.Approved, Investigational
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Testosterone.Approved
ClopidogrelThe metabolism of Testosterone can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClotrimazoleThe metabolism of Testosterone can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Testosterone.Approved
CobicistatThe metabolism of Testosterone can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Testosterone.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Testosterone.Approved
ConivaptanThe serum concentration of Testosterone can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Testosterone.Approved
Cortisone acetateCortisone acetate may increase the fluid retaining activities of Testosterone.Approved
CrizotinibThe metabolism of Testosterone can be decreased when combined with Crizotinib.Approved
CyclosporineTestosterone may increase the hepatotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Testosterone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Testosterone.Approved
DabrafenibThe serum concentration of Testosterone can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Testosterone.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Testosterone.Approved
DarunavirThe metabolism of Testosterone can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Testosterone can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Testosterone.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Testosterone.Approved
DeferasiroxThe serum concentration of Testosterone can be decreased when it is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfatedehydroepiandrosterone sulfate may increase the fluid retaining activities of Testosterone.Investigational
DelavirdineThe metabolism of Testosterone can be decreased when combined with Delavirdine.Approved
DesipramineThe metabolism of Testosterone can be decreased when combined with Desipramine.Approved
DesoximetasoneDesoximetasone may increase the fluid retaining activities of Testosterone.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the fluid retaining activities of Testosterone.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the fluid retaining activities of Testosterone.Experimental, Vet Approved
DexamethasoneThe serum concentration of Testosterone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the fluid retaining activities of Testosterone.Vet Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Testosterone.Approved, Illicit, Vet Approved
DicoumarolTestosterone may increase the anticoagulant activities of Dicoumarol.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Testosterone.Approved
DiflorasoneDiflorasone may increase the fluid retaining activities of Testosterone.Approved
DifluocortoloneDifluocortolone may increase the fluid retaining activities of Testosterone.Approved
DifluprednateDifluprednate may increase the fluid retaining activities of Testosterone.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Testosterone.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Testosterone.Approved
DihydroergotamineThe metabolism of Testosterone can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Testosterone.Illicit
DiltiazemThe metabolism of Testosterone can be decreased when combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Testosterone.Approved
DisopyramideTestosterone may increase the hypoglycemic activities of Disopyramide.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Testosterone.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Testosterone.Approved, Investigational, Vet Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Testosterone.Approved, Investigational
DoxycyclineThe metabolism of Testosterone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Testosterone can be decreased when combined with Dronedarone.Approved
DulaglutideTestosterone may increase the hypoglycemic activities of Dulaglutide.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Testosterone.Approved
EfavirenzThe serum concentration of Testosterone can be decreased when it is combined with Efavirenz.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Testosterone.Approved, Investigational
EltrombopagThe serum concentration of Testosterone can be increased when it is combined with Eltrombopag.Approved
EmpagliflozinTestosterone may increase the hypoglycemic activities of Empagliflozin.Approved
EnzalutamideThe serum concentration of Testosterone can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Testosterone.Approved, Investigational
EquileninEquilenin may increase the fluid retaining activities of Testosterone.Experimental
EquilinEquilin may increase the fluid retaining activities of Testosterone.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Testosterone.Approved, Investigational
ErythromycinThe metabolism of Testosterone can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Testosterone can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Testosterone can be decreased when combined with Esomeprazole.Approved, Investigational
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Testosterone.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Testosterone.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Testosterone.Approved
Estrone sulfateEstrone sulfate may increase the fluid retaining activities of Testosterone.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Testosterone.Approved
Ethyl biscoumacetateTestosterone may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Testosterone.Approved
EtravirineThe serum concentration of Testosterone can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Testosterone.Approved
ExenatideTestosterone may increase the hypoglycemic activities of Exenatide.Approved, Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Testosterone.Approved
FelodipineThe metabolism of Testosterone can be decreased when combined with Felodipine.Approved, Investigational
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Testosterone.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Testosterone.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Testosterone.Approved
FloxuridineThe metabolism of Testosterone can be decreased when combined with Floxuridine.Approved
fluasteronefluasterone may increase the fluid retaining activities of Testosterone.Investigational
FluconazoleThe metabolism of Testosterone can be decreased when combined with Fluconazole.Approved
FludrocortisoneFludrocortisone may increase the fluid retaining activities of Testosterone.Approved
FluindioneTestosterone may increase the anticoagulant activities of Fluindione.Investigational
FlumethasoneFlumethasone may increase the fluid retaining activities of Testosterone.Approved, Vet Approved
FlunisolideFlunisolide may increase the fluid retaining activities of Testosterone.Approved, Investigational
Fluocinolone AcetonideFluocinolone Acetonide may increase the fluid retaining activities of Testosterone.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the fluid retaining activities of Testosterone.Approved, Investigational
FluocortoloneFluocortolone may increase the fluid retaining activities of Testosterone.Approved, Withdrawn
FluorometholoneFluorometholone may increase the fluid retaining activities of Testosterone.Approved
FluorouracilThe metabolism of Testosterone can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Testosterone can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluprednideneFluprednidene may increase the fluid retaining activities of Testosterone.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the fluid retaining activities of Testosterone.Approved
FlurandrenolideFlurandrenolide may increase the fluid retaining activities of Testosterone.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Testosterone.Approved
Fluticasone PropionateFluticasone Propionate may increase the fluid retaining activities of Testosterone.Approved
FluvastatinThe metabolism of Testosterone can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Testosterone can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneFormestane may increase the fluid retaining activities of Testosterone.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Testosterone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Testosterone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Testosterone can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Testosterone can be increased when it is combined with Fusidic Acid.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Testosterone.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Testosterone.Approved
GemfibrozilThe metabolism of Testosterone can be decreased when combined with Gemfibrozil.Approved
GliclazideTestosterone may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideTestosterone may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideTestosterone may increase the hypoglycemic activities of Glipizide.Approved
GlyburideTestosterone may increase the hypoglycemic activities of Glyburide.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Testosterone.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Testosterone.Withdrawn
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Testosterone.Approved
HE3286HE3286 may increase the fluid retaining activities of Testosterone.Investigational
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Testosterone.Approved, Vet Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Testosterone.Approved
IdelalisibThe serum concentration of Testosterone can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Testosterone can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Testosterone.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Testosterone.Approved
IndinavirThe metabolism of Testosterone can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Testosterone.Approved, Investigational
Insulin AspartTestosterone may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirTestosterone may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineTestosterone may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineTestosterone may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanTestosterone may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproTestosterone may increase the hypoglycemic activities of Insulin Lispro.Approved
IrbesartanThe metabolism of Testosterone can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Testosterone.Approved, Investigational
IsavuconazoniumThe metabolism of Testosterone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Testosterone can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Testosterone can be decreased when combined with Isradipine.Approved
IstaroximeIstaroxime may increase the fluid retaining activities of Testosterone.Investigational
ItraconazoleThe metabolism of Testosterone can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Testosterone can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Testosterone.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Testosterone.Approved
KetoconazoleThe metabolism of Testosterone can be decreased when combined with Ketoconazole.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Testosterone.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Testosterone.Approved, Investigational
LanreotideTestosterone may increase the hypoglycemic activities of Lanreotide.Approved
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Testosterone.Approved, Investigational
LapatinibThe metabolism of Testosterone can be decreased when combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Testosterone.Approved
LeflunomideThe metabolism of Testosterone can be decreased when combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Testosterone.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Testosterone.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Testosterone.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Testosterone.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Testosterone.Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Testosterone.Approved
LiraglutideTestosterone may increase the hypoglycemic activities of Liraglutide.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Testosterone.Approved
LopinavirThe metabolism of Testosterone can be decreased when combined with Lopinavir.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Testosterone.Approved
LovastatinThe metabolism of Testosterone can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Testosterone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Testosterone can be increased when it is combined with Lumacaftor.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Testosterone.Approved, Investigational
ME-609ME-609 may increase the fluid retaining activities of Testosterone.Investigational
MecaserminTestosterone may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MedrysoneMedrysone may increase the fluid retaining activities of Testosterone.Approved
MelengestrolMelengestrol may increase the fluid retaining activities of Testosterone.Vet Approved
MetforminTestosterone may increase the hypoglycemic activities of Metformin.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Testosterone.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Testosterone.Approved, Vet Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Testosterone.Approved, Investigational
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Testosterone.Approved, Illicit
MifepristoneThe serum concentration of Testosterone can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolTestosterone may increase the hypoglycemic activities of Miglitol.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Testosterone.Approved
MitotaneThe serum concentration of Testosterone can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Testosterone.Approved, Investigational
MoclobemideThe metabolism of Testosterone can be decreased when combined with Moclobemide.Approved
ModafinilThe serum concentration of Testosterone can be decreased when it is combined with Modafinil.Approved, Investigational
MometasoneMometasone may increase the fluid retaining activities of Testosterone.Approved, Vet Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Testosterone.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Testosterone.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Testosterone.Approved
NafcillinThe serum concentration of Testosterone can be decreased when it is combined with Nafcillin.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Testosterone.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Testosterone.Approved, Vet Approved
NateglinideTestosterone may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022NCX 1022 may increase the fluid retaining activities of Testosterone.Investigational
NefazodoneThe metabolism of Testosterone can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Testosterone can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Testosterone can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Testosterone can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Testosterone can be decreased when combined with Nicardipine.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Testosterone.Approved
NilotinibThe metabolism of Testosterone can be decreased when combined with Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Testosterone.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Testosterone.Approved
OctreotideTestosterone may increase the hypoglycemic activities of Octreotide.Approved, Investigational
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Testosterone.Approved, Investigational
OlaparibThe metabolism of Testosterone can be decreased when combined with Olaparib.Approved
Oleoyl estroneOleoyl estrone may increase the fluid retaining activities of Testosterone.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Testosterone.Approved
OmeprazoleThe metabolism of Testosterone can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Testosterone can be increased when it is combined with Osimertinib.Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Testosterone.Approved, Vet Approved
PalbociclibThe serum concentration of Testosterone can be increased when it is combined with Palbociclib.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Testosterone.Approved, Investigational
PantoprazoleThe metabolism of Testosterone can be decreased when combined with Pantoprazole.Approved
ParamethasoneParamethasone may increase the fluid retaining activities of Testosterone.Approved
ParoxetineThe metabolism of Testosterone can be decreased when combined with Paroxetine.Approved, Investigational
PasireotideTestosterone may increase the hypoglycemic activities of Pasireotide.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Testosterone.Approved
PentamidineTestosterone may increase the hypoglycemic activities of Pentamidine.Approved
PentobarbitalThe metabolism of Testosterone can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenindioneTestosterone may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Testosterone can be increased when combined with Phenobarbital.Approved
PhenprocoumonTestosterone may increase the anticoagulant activities of Phenprocoumon.Approved
PhenytoinThe metabolism of Testosterone can be increased when combined with Phenytoin.Approved, Vet Approved
PioglitazoneThe metabolism of Testosterone can be decreased when combined with Pioglitazone.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Testosterone.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Testosterone.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Testosterone.Approved
PosaconazoleThe metabolism of Testosterone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideTestosterone may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Testosterone.Approved, Nutraceutical
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Testosterone.Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Testosterone.Approved
PrednicarbatePrednicarbate may increase the fluid retaining activities of Testosterone.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Testosterone.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Testosterone.Approved, Vet Approved
PregnenolonePregnenolone may increase the fluid retaining activities of Testosterone.Experimental
PrimidoneThe metabolism of Testosterone can be increased when combined with Primidone.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Testosterone.Approved, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Testosterone.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Testosterone.Approved
PyrimethamineThe metabolism of Testosterone can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe serum concentration of Testosterone can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Testosterone.Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Testosterone.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Testosterone.Approved
RabeprazoleThe metabolism of Testosterone can be decreased when combined with Rabeprazole.Approved, Investigational
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Testosterone.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Testosterone.Approved, Investigational
RepaglinideTestosterone may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Testosterone.Approved
RifabutinThe metabolism of Testosterone can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Testosterone can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Testosterone can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Testosterone.Approved, Investigational
RimexoloneRimexolone may increase the fluid retaining activities of Testosterone.Approved
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Testosterone.Approved, Investigational
RitonavirThe metabolism of Testosterone can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Testosterone.Approved
RolapitantThe serum concentration of Testosterone can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Testosterone.Approved, Investigational
RosiglitazoneThe metabolism of Testosterone can be decreased when combined with Rosiglitazone.Approved, Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Testosterone.Approved, Vet Approved
SaquinavirThe metabolism of Testosterone can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Testosterone.Approved
SecobarbitalThe metabolism of Testosterone can be increased when combined with Secobarbital.Approved, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Testosterone.Approved
SertralineThe metabolism of Testosterone can be decreased when combined with Sertraline.Approved
SildenafilThe metabolism of Testosterone can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Testosterone.Approved
SiltuximabThe serum concentration of Testosterone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Testosterone can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Testosterone.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Testosterone.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Testosterone.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Testosterone.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Testosterone.Experimental
St. John's WortThe serum concentration of Testosterone can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Testosterone can be increased when it is combined with Stiripentol.Approved
SulfadiazineThe metabolism of Testosterone can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Testosterone can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Testosterone can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SunitinibTestosterone may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Testosterone.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Testosterone.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Testosterone.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Testosterone.Approved
TelaprevirThe metabolism of Testosterone can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Testosterone can be decreased when combined with Telithromycin.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Testosterone.Approved
TeriflunomideThe serum concentration of Testosterone can be increased when it is combined with Teriflunomide.Approved
ThiotepaThe metabolism of Testosterone can be decreased when combined with Thiotepa.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Testosterone.Approved
TiclopidineThe metabolism of Testosterone can be decreased when combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Testosterone.Approved
TixocortolTixocortol may increase the fluid retaining activities of Testosterone.Approved
TocilizumabThe serum concentration of Testosterone can be decreased when it is combined with Tocilizumab.Approved
TolazamideTestosterone may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideThe metabolism of Testosterone can be decreased when combined with Tolbutamide.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Testosterone.Approved
TopiramateThe metabolism of Testosterone can be decreased when combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Testosterone.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Testosterone.Approved, Investigational
TranylcypromineThe metabolism of Testosterone can be decreased when combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Testosterone.Approved
TriamcinoloneTriamcinolone may increase the fluid retaining activities of Testosterone.Approved, Vet Approved
TrimethoprimThe metabolism of Testosterone can be decreased when combined with Trimethoprim.Approved, Vet Approved
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Testosterone.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Testosterone.Approved
Valproic AcidThe metabolism of Testosterone can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Testosterone can be decreased when combined with Valsartan.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Testosterone.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Testosterone.Approved
VenlafaxineThe metabolism of Testosterone can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Testosterone can be decreased when combined with Verapamil.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Testosterone.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Testosterone.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Testosterone.Approved
VoriconazoleThe metabolism of Testosterone can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinTestosterone may increase the anticoagulant activities of Warfarin.Approved
ZafirlukastThe metabolism of Testosterone can be decreased when combined with Zafirlukast.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Testosterone.Approved
ZiprasidoneThe metabolism of Testosterone can be decreased when combined with Ziprasidone.Approved
Food InteractionsNot Available
References
Synthesis Reference

Merle G. Wovcha, Frederick J. Antosz, John M. Beaton, Alfred B. Garcia, Leo A. Kominek, “Process for preparing 9.alpha.-OH testosterone.” U.S. Patent US4221868, issued November, 1977.

US4221868
General References
  1. Freeman ER, Bloom DA, McGuire EJ: A brief history of testosterone. J Urol. 2001 Feb;165(2):371-3. [PubMed:11176375 ]
  2. Hoberman JM, Yesalis CE: The history of synthetic testosterone. Sci Am. 1995 Feb;272(2):76-81. [PubMed:7817189 ]
  3. Authors unspecified: Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility. Lancet. 1990 Oct 20;336(8721):955-9. [PubMed:1977002 ]
  4. Dean JD, Carnegie C, Rodzvilla J, Smith T: Long-term effects of testim(r) 1% testosterone gel in hypogonadal men. Rev Urol. 2004;6 Suppl 6:S22-9. [PubMed:16985908 ]
External Links
ATC CodesG03EA02G03BA03
AHFS Codes
  • 68:08.00
PDB EntriesNot Available
FDA labelDownload (738 KB)
MSDSDownload (49.6 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.973
Caco-2 permeable+0.8984
P-glycoprotein substrateSubstrate0.6498
P-glycoprotein inhibitor IInhibitor0.5489
P-glycoprotein inhibitor IINon-inhibitor0.8923
Renal organic cation transporterNon-inhibitor0.7324
CYP450 2C9 substrateNon-substrate0.8167
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7739
CYP450 1A2 substrateNon-inhibitor0.9005
CYP450 2C9 inhibitorNon-inhibitor0.95
CYP450 2D6 inhibitorNon-inhibitor0.9452
CYP450 2C19 inhibitorNon-inhibitor0.6668
CYP450 3A4 inhibitorNon-inhibitor0.8812
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8683
Ames testNon AMES toxic0.9382
CarcinogenicityNon-carcinogens0.9483
BiodegradationNot ready biodegradable0.9174
Rat acute toxicity1.6259 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8938
hERG inhibition (predictor II)Non-inhibitor0.7163
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Heather drug co inc
  • Valeant pharmaceuticals international
  • Schering corp sub schering plough corp
  • Novartis pharmaceuticals corp
  • Impax laboratories inc
  • Eli lilly and co
  • Purepac pharmaceutical co
  • Private formulations inc
  • Tablicaps inc
  • Usl pharma inc
  • Inwood laboratories inc sub forest laboratories inc
  • Kv pharmaceutical co
  • Lannett co inc
  • Parke davis div warner lambert co
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Alza corp
  • Unimed pharmaceuticals inc
  • Auxilium pharmaceuticals
  • Par pharmaceutical
  • Watson laboratories
  • Slate pharmaceuticals inc
  • Columbia laboratories inc
  • Pharmacia and upjohn co
  • Bedford laboratories div ben venue laboratories inc
  • Paddock laboratories inc
  • Sandoz canada inc
  • Synerx pharma llc
  • Endo pharmaceutical solutions inc
  • Solvay Pharmaceuticals, Inc.
Packagers
Dosage forms
FormRouteStrength
CapsuleOral40 mg
PatchTransdermal12.2 mg
PatchTransdermal2 mg/d
PatchTransdermal24.3 mg
PatchTransdermal4 mg/d
GelTransdermal10 mg/g
GelTransdermal16.2 mg/g
GelTransdermal25 mg/2.5g
InjectionIntramuscular250 mg/mL
SolutionTopical2 %
SolutionTopical30 mg/1.5mL
SolutionIntramuscular200 mg
Injection, solutionIntramuscular100 mg/mL
Injection, solutionIntramuscular200 mg/mL
SolutionIntramuscular100 mg
PatchTransdermal300 micrograms/24hours
SuspensionIntramuscular100 mg
GelNasal4.5 %
GelNasal5.5 mg/1
SolutionIntramuscular
LiquidIntramuscular200 mg
TabletBuccal30 mg/1
GelTransdermal50 mg/5g
GelTopical1 %
PelletSubcutaneous75 mg/1
GelTopical12.5 mg/1.25g
GelTopical50 mg/5g
Gel, meteredTopical10 mg/.5g
Gel, meteredTopical12.5 mg/1
PelletOral100 mg/1
PelletOral200 mg/1
PelletOral25 mg/1
PelletOral37.5 mg/1
PelletOral50 mg/1
PelletOral87.5 mg/1
InjectionIntramuscular200 mg/mL
LiquidIntramuscular100 mg
Prices
Unit descriptionCostUnit
AndroGel Pump 1% Gel (1 Box Contains Two 75 gm Bottles)290.63USD box
Androderm 60 2.5 mg/24hr Patches 1 Box = 60 Patches278.56USD box
Androderm 30 5 mg/24hr Patches 1 Box = 30 Patches277.53USD box
AndroGel (each Box Contains Thirty - 50 mg/5 gm Packets) 150 gm Box274.58USD box
AndroGel (each Box Contains Thirty - 25 mg/2.5 gm Packets) 75 gm Box270.61USD box
Delatestryl 200 mg/ml Oil 5ml Vial93.98USD vial
Testosterone Cypionate 200 mg/ml Oil 10ml Vial88.99USD vial
Testosterone Cypionate 100 mg/ml Oil 10ml Vial57.99USD vial
Depo-Testosterone 200 mg/ml Oil 1ml Vial34.99USD vial
Testosterone cypionate powd32.74USD g
Testosterone Cypionate 200 mg/ml Oil 1ml Vial28.99USD vial
Depo-testosterone 200 mg/ml28.63USD ml
Testopel 75 mg pellets27.5USD pellet
Testosterone cyp 200 mg/ml23.18USD ml
Delatestryl 200 mg/ml vial19.86USD ml
Testred 10 mg capsule17.6USD capsule
Testosterone enan 200 mg/ml16.99USD ml
Testosterone Enanthate 200 mg/ml Oil16.66USD ml
Depo-Testosterone 200 mg/ml Oil13.23USD ml
Android 10 mg capsule11.91USD capsule
Delatestryl 200 mg/ml10.75USD ml
Testim 1% Gel 5 gm Tube10.08USD tube
Androderm 5 mg/24hr patch10.06USD patch
Methyltestosterone powder8.54USD g
Depo-Testosterone 100 mg/ml Oil7.87USD ml
Depo-testosterone 100 mg/ml vial7.67USD ml
Testosterone powder6.25USD g
Testosterone propionate powder6.25USD g
Testosterone cyp 100 mg/ml5.91USD ml
Androderm 2.5 mg/24hr patch5.03USD patch
Methitest 10 mg tablet4.84USD tablet
Striant 30 mg Miscellaneous4.32USD ea
Striant 30 mg mucoadhesive4.31USD each
Depo-Testosterone Cypionate 100 mg/ml2.98USD ml
Testim 1%(50 mg) gel2.47USD g
Testosterone Cypionate 100 mg/ml2.23USD ml
Androgel 1% gel pump1.92USD g
First-testosterone mc 2% cr0.91USD g
First 2% testosterone oint0.88USD g
First-Testosterone 2% Ointment0.86USD gm
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1332570 No1994-10-182011-10-18Canada
CA2366856 No2006-05-162020-03-27Canada
US5152997 No1993-12-112010-12-11Us
US5840327 No1996-08-152016-08-15Us
US6248358 No1999-08-232019-08-23Us
US6299900 No1997-02-192017-02-19Us
US6319913 No1998-11-092018-11-09Us
US6348210 No1999-11-102019-11-10Us
US6503894 Yes2001-03-012021-03-01Us
US6579865 No1998-11-092018-11-09Us
US6818226 No1997-02-192017-02-19Us
US6923983 No1997-02-192017-02-19Us
US7320968 No2005-01-182025-01-18Us
US7608605 No2003-04-212023-04-21Us
US7608606 No2003-04-212023-04-21Us
US7608607 No2003-04-212023-04-21Us
US7608608 No2003-04-212023-04-21Us
US7608609 No2003-04-212023-04-21Us
US7608610 No2003-04-212023-04-21Us
US7718640 No2007-03-142027-03-14Us
US7935690 No2003-04-212023-04-21Us
US8063029 No2003-04-212023-04-21Us
US8071075 No1997-02-192017-02-19Us
US8178518 No2003-04-212023-04-21Us
US8338395 No2006-02-272026-02-27Us
US8419307 No2007-02-262027-02-26Us
US8435944 No2007-09-272027-09-27Us
US8466136 No2006-10-122026-10-12Us
US8466137 No2006-10-122026-10-12Us
US8466138 No2006-10-122026-10-12Us
US8486925 No2006-10-122026-10-12Us
US8574622 No2004-02-042024-02-04Us
US8729057 No2006-10-122026-10-12Us
US8741881 No2006-10-122026-10-12Us
US8754070 No2006-10-122026-10-12Us
US8759329 No2006-10-122026-10-12Us
US8784869 No2004-02-042024-02-04Us
US8784878 No2003-07-132023-07-13Us
US8784882 No2004-02-042024-02-04Us
US8785426 No2014-02-112034-02-11Us
US8807861 No2007-02-262027-02-26Us
US8877230 No2004-02-042024-02-04Us
US8993520 No2006-06-022026-06-02Us
US9125816 Yes2001-03-022021-03-02Us
US9132089 Yes2001-03-022021-03-02Us
US9180194 No2006-06-022026-06-02Us
US9289586 No2007-02-262027-02-26Us
US9295675 No2014-02-112034-02-11Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point155 °CPhysProp
water solubility23.4 mg/L (at 25 °C)YALKOWSKY,SH & HE,Y (2003)
logP3.32HANSCH,C ET AL. (1995)
Caco2 permeability-4.34ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0333 mg/mLALOGPS
logP2.99ALOGPS
logP3.37ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)19.09ChemAxon
pKa (Strongest Basic)-0.88ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area37.3 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity84.43 m3·mol-1ChemAxon
Polarizability34.02 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (13.5 KB)
Spectra
Spectrum TypeDescriptionSplash Key
GC-MSGC-MS Spectrum - GC-MS (1 TMS)splash10-004i-3910000000-d6ace9b7f8aff4dd46d0View in MoNA
GC-MSGC-MS Spectrum - GC-MS (2 TMS)splash10-053u-1920200000-db3504f562c54e6e1bbbView in MoNA
GC-MSGC-MS Spectrum - GC-MS (1 MEOX; 1 TMS)splash10-004l-3910000000-b43cd1ee268a855c8aa0View in MoNA
GC-MSGC-MS Spectrum - GC-MS (1 MEOX; 1 TMS)splash10-004l-3910000000-356ddfa8ddf8e551278dView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)splash10-000i-0090000000-914b212f1dbb7fb7b1acView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)splash10-052b-9800000000-d2e38d44d2f16d0a4203View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)splash10-052b-9300000000-6830823fa12b40e784a2View in MoNA
LC-MS/MSLC-MS/MS Spectrum - EI-B (JEOL JMS-01-SG-2) , Positivesplash10-0597-7920000000-dde7fba02fcbcec2d665View in MoNA
LC-MS/MSLC-MS/MS Spectrum - EI-B (HITACHI RMU-6E) , Positivesplash10-05fs-4920000000-ccd839134de79f179f9eView in MoNA
LC-MS/MSLC-MS/MS Spectrum - EI-B (HITACHI M-80) , Positivesplash10-00ds-0950000000-48c1f79091d708072f30View in MoNA
MSMass Spectrum (Electron Ionization)splash10-00dv-5940000000-5e22fba0c369374c75dfView in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassAndrostane steroids
Direct ParentAndrogens and derivatives
Alternative Parents
Substituents
  • Androgen-skeleton
  • 17-hydroxysteroid
  • Oxosteroid
  • Hydroxysteroid
  • 3-oxosteroid
  • 3-oxo-delta-4-steroid
  • Delta-4-steroid
  • Cyclic alcohol
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins. Transcription activation is down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3.
Gene Name:
AR
Uniprot ID:
P10275
Molecular Weight:
98987.9 Da
References
  1. Small EJ, Ryan CJ: The case for secondary hormonal therapies in the chemotherapy age. J Urol. 2006 Dec;176(6 Pt 2):S66-71. [PubMed:17084172 ]
  2. Omwancha J, Brown TR: Selective androgen receptor modulators: in pursuit of tissue-selective androgens. Curr Opin Investig Drugs. 2006 Oct;7(10):873-81. [PubMed:17086931 ]
  3. Petraki CD, Sfikas CP: Histopathological changes induced by therapies in the benign prostate and prostate adenocarcinoma. Histol Histopathol. 2007 Jan;22(1):107-18. [PubMed:17128417 ]
  4. Maudsley S, Davidson L, Pawson AJ, Freestone SH, Lopez de Maturana R, Thomson AA, Millar RP: Gonadotropin-releasing hormone functionally antagonizes testosterone activation of the human androgen receptor in prostate cells through focal adhesion complexes involving Hic-5. Neuroendocrinology. 2006;84(5):285-300. Epub 2007 Jan 4. [PubMed:17202804 ]
  5. Lapauw B, Goemaere S, Crabbe P, Kaufman JM, Ruige JB: Is the effect of testosterone on body composition modulated by the androgen receptor gene CAG repeat polymorphism in elderly men? Eur J Endocrinol. 2007 Mar;156(3):395-401. [PubMed:17322500 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Zhang T, Zhu Y, Gunaratna C: Rapid and quantitative determination of metabolites from multiple cytochrome P450 probe substrates by gradient liquid chromatography-electrospray ionization-ion trap mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Nov 25;780(2):371-9. [PubMed:12401364 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
  4. Source [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name:
CYP19A1
Uniprot ID:
P11511
Molecular Weight:
57882.48 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Serotonin binding
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine.
Gene Name:
MAOA
Uniprot ID:
P21397
Molecular Weight:
59681.27 Da
References
  1. Sjoberg RL, Ducci F, Barr CS, Newman TK, Dell'osso L, Virkkunen M, Goldman D: A non-additive interaction of a functional MAO-A VNTR and testosterone predicts antisocial behavior. Neuropsychopharmacology. 2008 Jan;33(2):425-30. Epub 2007 Apr 11. [PubMed:17429405 ]
  2. Hoff KM: Interaction of testosterone with monoamineoxidase in mouse brain maturation. Gen Pharmacol. 1977;8(1):55-7. [PubMed:590724 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, nad(p)h as one donor, and incorporation of one atom of oxygen
Specific Function:
Catalyzes the side-chain cleavage reaction of cholesterol to pregnenolone.
Gene Name:
CYP11A1
Uniprot ID:
P05108
Molecular Weight:
60101.87 Da
References
  1. Kostic TS, Stojkov NJ, Bjelic MM, Mihajlovic AI, Janjic MM, Andric SA: Pharmacological doses of testosterone upregulated androgen receptor and 3-Beta-hydroxysteroid dehydrogenase/delta-5-delta-4 isomerase and impaired leydig cells steroidogenesis in adult rats. Toxicol Sci. 2011 Jun;121(2):397-407. doi: 10.1093/toxsci/kfr063. Epub 2011 Apr 6. [PubMed:21427060 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Molecular Weight:
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a coumarin 7-hydroxylase activity. Active in the metabolic activation of hexamethylphosphoramide, N,N-dimethylaniline, 2'-methoxyacetophenone, N-nitrosomethylphenylamine, and the tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Possesses phenacetin O-deethylation activity.
Gene Name:
CYP2A13
Uniprot ID:
Q16696
Molecular Weight:
56687.095 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Monooxygenase activity
Specific Function:
Exhibits low testosterone 6-beta-hydroxylase activity.
Gene Name:
CYP3A43
Uniprot ID:
Q9HB55
Molecular Weight:
57669.21 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
other/unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Pardridge WM: Serum bioavailability of sex steroid hormones. Clin Endocrinol Metab. 1986 May;15(2):259-78. [PubMed:3521955 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
other/unknown
General Function:
Androgen binding
Specific Function:
Functions as an androgen transport protein, but may also be involved in receptor mediated processes. Each dimer binds one molecule of steroid. Specific for 5-alpha-dihydrotestosterone, testosterone, and 17-beta-estradiol. Regulates the plasma metabolic clearance rate of steroid hormones by controlling their plasma concentration.
Gene Name:
SHBG
Uniprot ID:
P04278
Molecular Weight:
43778.755 Da
References
  1. Pardridge WM: Serum bioavailability of sex steroid hormones. Clin Endocrinol Metab. 1986 May;15(2):259-78. [PubMed:3521955 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Lu R, Kanai N, Bao Y, Wolkoff AW, Schuster VL: Regulation of renal oatp mRNA expression by testosterone. Am J Physiol. 1996 Feb;270(2 Pt 2):F332-7. [PubMed:8779895 ]
  2. Kanai N, Lu R, Bao Y, Wolkoff AW, Vore M, Schuster VL: Estradiol 17 beta-D-glucuronide is a high-affinity substrate for oatp organic anion transporter. Am J Physiol. 1996 Feb;270(2 Pt 2):F326-31. [PubMed:8779894 ]
  3. Bossuyt X, Muller M, Hagenbuch B, Meier PJ: Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther. 1996 Mar;276(3):891-6. [PubMed:8786566 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
References
  1. Kobayashi Y, Hirokawa N, Ohshiro N, Sekine T, Sasaki T, Tokuyama S, Endou H, Yamamoto T: Differential gene expression of organic anion transporters in male and female rats. Biochem Biophys Res Commun. 2002 Jan 11;290(1):482-7. [PubMed:11779196 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.
Gene Name:
SLC22A7
Uniprot ID:
Q9Y694
Molecular Weight:
60025.025 Da
References
  1. Kobayashi Y, Hirokawa N, Ohshiro N, Sekine T, Sasaki T, Tokuyama S, Endou H, Yamamoto T: Differential gene expression of organic anion transporters in male and female rats. Biochem Biophys Res Commun. 2002 Jan 11;290(1):482-7. [PubMed:11779196 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ, Ganapathy V: Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem. 1998 Dec 4;273(49):32776-86. [PubMed:9830022 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Katoh M, Nakajima M, Yamazaki H, Yokoi T: Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur J Pharm Sci. 2001 Feb;12(4):505-13. [PubMed:11231118 ]
  2. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Virus receptor activity
Specific Function:
The hepatic sodium/bile acid uptake system exhibits broad substrate specificity and transports various non-bile acid organic compounds as well. It is strictly dependent on the extracellular presence of sodium.(Microbial infection) Acts as a receptor for hepatitis B virus.
Gene Name:
SLC10A1
Uniprot ID:
Q14973
Molecular Weight:
38118.64 Da
References
  1. Schroeder A, Eckhardt U, Stieger B, Tynes R, Schteingart CD, Hofmann AF, Meier PJ, Hagenbuch B: Substrate specificity of the rat liver Na(+)-bile salt cotransporter in Xenopus laevis oocytes and in CHO cells. Am J Physiol. 1998 Feb;274(2 Pt 1):G370-5. [PubMed:9486191 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Toxin transporter activity
Specific Function:
Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
Gene Name:
SLC22A3
Uniprot ID:
O75751
Molecular Weight:
61279.485 Da
References
  1. Tzvetkov MV, Vormfelde SV, Balen D, Meineke I, Schmidt T, Sehrt D, Sabolic I, Koepsell H, Brockmoller J: The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther. 2009 Sep;86(3):299-306. doi: 10.1038/clpt.2009.92. Epub 2009 Jun 17. [PubMed:19536068 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Symporter activity
Specific Function:
Sodium-ion dependent, low affinity carnitine transporter. Probably transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Relative uptake activity ratio of carnitine to TEA is 1.78. A key substrate of this transporter seems to be ergothioneine (ET).
Gene Name:
SLC22A4
Uniprot ID:
Q9H015
Molecular Weight:
62154.48 Da
References
  1. Tzvetkov MV, Vormfelde SV, Balen D, Meineke I, Schmidt T, Sehrt D, Sabolic I, Koepsell H, Brockmoller J: The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther. 2009 Sep;86(3):299-306. doi: 10.1038/clpt.2009.92. Epub 2009 Jun 17. [PubMed:19536068 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Janvilisri T, Venter H, Shahi S, Reuter G, Balakrishnan L, van Veen HW: Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51. Epub 2003 Mar 28. [PubMed:12668685 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 02, 2016 03:58